Zimp10 Inhibitors
Chemical inhibitors of Zimp10 can function by modulating the activity of several cellular signaling pathways and transcription factors with which Zimp10 interacts as a coactivator. PD 0332991, for instance, targets CDK4/6, vital enzymes for cell cycle progression. Inhibition of these kinases by PD 0332991 can lead to a cell cycle arrest at the G1 phase, hence functionally limiting the coactivator role of Zimp10 in promoting cell cycle progression. Similarly, Nutlin-3, by antagonizing MDM2, stabilizes and activates p53, a transcription factor known to induce cell cycle arrest and apoptosis. Since Zimp10 enhances the transcriptional activity of p53, Nutlin-3's stabilization of p53 can further influence the gene expression profiles associated with Zimp10's coactivator functions.
Additionally, Trichostatin A, through its inhibition of HDAC, can disrupt the chromatin structure and alter gene expression patterns where Zimp10 is involved, leading to an effective inhibition of its role in gene regulation. LY294002, a PI3K inhibitor, can attenuate the PI3K/AKT/mTOR signaling pathway, leading to a decrease in cellular proliferation and survival signals, which are processes where Zimp10 is known to participate. U0126 and PD98059, both MEK inhibitors, prevent the activation of the ERK pathway. Since Zimp10 interacts with transcription factors regulated by the MAPK/ERK pathway, these inhibitors can indirectly modulate the transcriptional activity influenced by Zimp10. GW501516, a PPARδ agonist, can alter PPARδ activity and thus affect transcriptional programs where Zimp10 acts as a coactivator, particularly those related to metabolism. Inhibitors like SP600125 and SB203580, which target JNK and p38 MAP kinase respectively, can reduce the coactivator function of Zimp10 on transcription factors activated by these kinases. Lastly, Rapamycin's inhibition of mTOR can lead to a reduction in the coactivator function of Zimp10 associated with the mTOR signaling pathway, encompassing effects on protein synthesis and cell growth.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib specifically inhibits CDK4/6, which are crucial for cell cycle progression from G1 to S phase. Zimp10, as a coactivator for androgen receptor (AR) signaling, is involved in cell cycle progression of prostate cancer cells. Inhibition of CDK4/6 can disrupt the progression of the cell cycle, thereby functionally inhibiting the role of Zimp10 in facilitating AR-mediated cell cycle progression. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
Nutlin-3 antagonizes MDM2, leading to the stabilization and activation of p53. Zimp10 has been shown to enhance p53 transcriptional activity and thus, is functionally linked to the p53 pathway. By activating p53, Nutlin-3 can promote the transcription of genes involved in cell cycle arrest and apoptosis, which can counteract the coactivator function of Zimp10 in promoting cell proliferation. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase (HDAC) inhibitor that leads to an increase in acetylated histones, thereby affecting gene expression. Zimp10 interacts with components of the transcription machinery, and HDAC inhibition can alter the chromatin structure and transcriptional activity where Zimp10 is involved, leading to a functional inhibition of its activity in gene regulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of phosphatidylinositol 3-kinase (PI3K), which is part of the PI3K/AKT/mTOR pathway, a key signaling pathway in many cellular processes including metabolism, growth, and survival. Zimp10 has been implicated in the regulation of this pathway. Inhibition of PI3K can reduce AKT phosphorylation and activity, which can indirectly inhibit the coactivator function of Zimp10 in this pathway, leading to reduced cell survival and proliferation that Zimp10 may promote. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 specifically inhibits MEK1/2, key kinases in the MAPK/ERK pathway. Zimp10 has been shown to interact with transcription factors that are regulated by the MAPK/ERK pathway. Inhibition of MEK1/2 leads to reduced ERK phosphorylation and activity, which can indirectly inhibit the coactivator function of Zimp10 on these transcription factors, impacting cellular differentiation and proliferation that Zimp10 might enhance. | ||||||
GW501516 | 317318-70-0 | sc-202642 sc-202642A | 1 mg 5 mg | $82.00 $179.00 | 28 | |
GW501516 is a PPARδ agonist that can influence the activity of PPARδ-related transcription factors. As Zimp10 can act as a transcriptional coactivator, its activity could be functionally inhibited by the alteration of PPARδ activity, which could lead to a shift in the transcriptional programs that Zimp10 might enhance, particularly in metabolism and fatty acid oxidation where Zimp10 could be involved. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in the regulation of apoptosis and cell differentiation. Zimp10 acts as a coactivator of transcription factors, some of which are targets of JNK signaling. By inhibiting JNK, SP600125 can reduce the functional activation of transcription factors that Zimp10 may coactivate, thereby inhibiting the coactivator function of Zimp10 in JNK-responsive gene expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase, which is implicated in inflammatory responses and stress-induced signaling. Zimp10 can associate with transcription factors that are activated by p38 MAPK. Inhibition of p38 MAPK by SB203580 can disrupt the activation of these transcription factors, indirectly inhibiting the coactivator function of Zimp10 in stress response gene expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a key regulator of cell growth and metabolism. Zimp10 is known to interact with the PI3K/AKT/mTOR signaling pathway. By inhibiting mTOR, Rapamycin can lead to a decrease in protein synthesis and cell proliferation. This can indirectly inhibit the coactivator function of Zimp10 in promoting the growth and survival signals that are mediated via the mTOR pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD980It seems that your message got cut off at the end. If you were asking for information about PD98059, here's a brief description: | ||||||